Unique ID issued by UMIN | UMIN000018431 |
---|---|
Receipt number | R000021341 |
Scientific Title | Retrospective study of Erythropoiesis STimulating Agent dose ReducTion on hemodialysis patients by using anti-thrombogenic membrane |
Date of disclosure of the study information | 2015/08/31 |
Last modified on | 2018/09/26 00:17:17 |
Retrospective study of Erythropoiesis STimulating Agent dose ReducTion on hemodialysis patients by using anti-thrombogenic membrane
RESTART Study
Retrospective study of Erythropoiesis STimulating Agent dose ReducTion on hemodialysis patients by using anti-thrombogenic membrane
RESTART Study
Japan |
Chronic renal disease
Nephrology |
Others
NO
It is examined whether switching to anti-thrombogenic dialyzer affects the responsibility to ESA.
Efficacy
Responsibility for erythropoiesis stimulating agent 6 or 12 months after the beginning of observation.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Outpatients who had been treated with more than 4h dialysis three times a week.
2) Patients who had been treated more than 3 months with polysulfone type dialyzers excluding NV, (their dialysis vintages are more than 3 months).
3) Patients who had been more than 20 years old.
4) Patients to whom erythropoiesis stimulating agent had been prescribed
For 3 months before the beginning of observation and during observation period, patients who had fulfilled conditions below were excluded.
1) Patients who had been treated with other renal insufficiency therapies, continuous ambulatory peritoneal dialysis and hemodiafiltration, excluding hemodialysis.
2) Patients to whom Epoetin Beta Pegol (CERA) had been prescribed.
3) Patients to whom blood transfusion had been conducted.
4) Patients who had been hospitalized for more than 2 weeks.
5) Patients who had become pregnant or given birth.
6) Patients who had hematologic diseases excluding renal anemia.
7) Patients who had been treated for a malignant tumor.
8) Patients who is judged as the inadequate subject of this study by the doctor.
400
1st name | |
Middle name | |
Last name | Takatoshi Kakuta |
Tokai University Hachioji Hospital
ivision of Nephrology, Endocrinology and Metabolism
1838 Ishikawa-nachi, Hachioji-shi, Tokyo
042-639-1111
kakuta@is.icc.u-tokai.ac.jp
1st name | |
Middle name | |
Last name | Takatoshi Kakuta |
Tokai University Hachioji Hospital
ivision of Nephrology, Endocrinology and Metabolism
1838 Ishikawa-nachi, Hachioji-shi, Tokyo
042-639-1111
kakuta@is.icc.u-tokai.ac.jp
RESTART Study group
TORAY Industries Inc.
Profit organization
NO
2015 | Year | 08 | Month | 31 | Day |
Unpublished
Completed
2015 | Year | 04 | Month | 10 | Day |
2015 | Year | 09 | Month | 01 | Day |
2017 | Year | 09 | Month | 01 | Day |
In previous prospective clinical study, TORAYLIGHT NV had a possibility to reduce erythropoiesis stimulating agent.
2015 | Year | 07 | Month | 27 | Day |
2018 | Year | 09 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021341